The results of a phase 2 trial of MSD’s ROR1 inhibitor zilovertamab vedotin (zilo-V) back up the company's decision to push the antibody-drug conjugate (ADC) into a phase 3 programme. Presented at the ...
Exploring the biggest questions of our time with the help of the world's greatest thinkers. Host Manoush Zomorodi inspires us to learn more about the world, our communities, and most importantly, ...
Human rights are under assault [...] This year’s theme reminds us that human rights are about building the future — right now [...] We must stand up for all rights — always." UN Secretary-General ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback